warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
COG AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
Brief Description  
This randomized phase III trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed high-risk acute lymphoblastic leukemia, testing Clofarabine (IND#73789, NSC#606869) in the very-high risk stratum.
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Lymphoid Leukemia
Status  
OPEN
Start Date  
10/19/2016
IRB Number  
02-12-13B
Principal Investigator  
Kaplan, Joel Adam
Contact Name  
Sceria Jenkins

For More Information, Contact  Sceria  , Jenkins
Phone:  980-442-2323 Fax:    
Email:  sceria.jenkins@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204
Close